Abeona therapeutics announces two presentations related to its rdeb clinical program at the society for pediatric dermatology 45th annual meeting

New york and cleveland, july 10, 2020 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced that two poster presentations related to its clinical program for recessive dystrophic epidermolysis bullosa (rdeb) were featured at the society for pediatric dermatology (spd) 45th annual meeting. the first poster includes a detailed analysis of patients with rdeb in the eb-101 phase 1/2a trial showing that wound healing following eb-101 treatment was associated with improved long-term pain relief. a separate poster provides insights on the significant disease burden associated with rdeb, highlighting data from a literature review on the clinical characteristics, humanistic consequences and economic impact of living with rdeb on patients and their families.
ABEO Ratings Summary
ABEO Quant Ranking